The global lyophilized injectable market is projected to register at a moderate-paced (Compound Annual Growth Rate) CAGR of 5.8% over the forecast period. The lyophilized injectable market is currently valued at US$ 3043.55 Million in 2023. By 2033, demand for lyophilized injectables is expected to reach a high of US$ 5348.56 Million.
This growth in the adoption of lyophilized injectables is supported by the following:
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Trials that are still going on are revealing added information about the safety and effectiveness of new lyophilized medicines that are being used to treat COVID-19. Manufacturers in the global lyophilized injectable market are getting licenses from the USA Food and Drug Administration (FDA) for the Emergency Use Authorization (EUA) of these products so they can treat people with severe COVID-19 symptoms.
Since the COVID-19 pandemic, companies that export lyophilized injectables have worked harder to obtain authorization from authorities like the Drug Controller General of India (DCGI) so that their goods may be used in India for limited emergency purposes. As more medications, like Remdesivir, get approved, the need for lyophilized injections will inevitably rise. The Food and Drug Administration (FDA) and other regulatory agencies have given their approvals for the following:
As a result, the expansion of the market for lyophilized injections is being driven by the rising number of approvals being granted all over the world.
| Attribute | Details |
|---|---|
| Market Value (2023) | US$ 3043.55 Million |
| Market Value (2033) | US$ 5348.56 Million |
| CAGR | 5.8% |
There has been a significant increase in the number of businesses throughout the world using lyophilization technology because of the superior quality and longer shelf life of lyophilized medications. There has been a substantial uptick in the utilization of lyophilized injection pharmaceuticals by global contract research and manufacturing firms during the past few years. The primary motivation for this change is to supply final consumers with better goods. Opportunities in the global lyophilized injectable market are being created by reasons such as the fast growth of Contract Research Manufacturing Services (CRAMS).
Due to their safety and capacity to fulfill their stated functions, lyophilized products have witnessed a substantial increase in usage recently compared to non-lyophilized ones. Besides this, the cold chain is not necessary for these items. Therefore, they contribute to lower carbon footprints and total expenses. As a result of these factors, the lyophilized injectable market is predicted to expand into new lucrative areas in the coming years.
The expansion of the sector for lyophilized injection drugs may be hampered by several incidents involving the recall of products containing complex medications. In recent years, there has been a significant increase in product recalls that have been reported by manufacturers. These recalls have been brought about by the presence of unwanted foreign substances or by adverse drug effects. Recalls have the potential to harm a company's reputation as well as its ability to generate revenue.
Principal Consultant
It is anticipated that the injection supplies pharmaceuticals market coming from the retail pharmacy segment is anticipated to hold more than 30 percent of the total industry share by 2033. As they provide convenient access, cheap rates, high-end customer care, and an extensive selection of items, retail pharmacies have emerged as one of the primary distribution channels. This is because retail pharmacies offer all these benefits.
In addition to this, pharmacies and other retail locations sell pharmaceuticals and offer individuals individualized guidance that caters to their specific healthcare issues and needs. In recent years, there has been a considerable increase in the number of retail pharmacies as well as pharmacy chains, which is indicative of a strong preference among customers for this type of distribution channel.
It is anticipated that the demand for lyophilized injectable medicines in the prefilled device category is likely to reach US$210 Billion by 2033. Prefilled devices are becoming increasingly popular because of their ability to reduce the amount of time that patients are required to wait during hospital visits and to improve the level of medical care.
Along with ensuring the safe and convenient delivery of treatment, it also guarantees an elevated level of precision in the dosing of medications. Although the introduction of prefilled devices across a spectrum of drug classes and therapeutic categories can look quite different, it is anticipated that demand for the product is likely to remain steady.
The lyophilized Injectable market is estimated to grow profitably in North America in the upcoming years because of the rising frequency of disorders in the United States. . The presence of significant manufacturers, like Fresenius Kabi and Merck & Co. Inc., and Amneal Pharmaceutical, both are involved in the production of lyophilized injections and helping to drive growth in the USA Lyophilized Injectable Market. Furthermore, the increasing number of product approvals made by regulatory authorities in North America is anticipated to be fueling the expansion of the USA Lyophilized Injectable Market.
It is expected that the size of the lyophilized injectable market in Europe is expected to exceed US$185 Billion by 2030. This region is predicted to become a suitable region for the expansion of existing businesses due to the rising incidence of cancer and other ailments. Europe, which has one of the oldest populations overall, is home to some of the world's oldest individuals. The growth of the senior population, which has a compromised immunological and metabolic system and is consequently at a higher risk of developing life-threatening illnesses, is another significant factor that is projected to propel the sector. According to several studies, the native populations of Belgium, the Netherlands, Denmark, and Ireland have the greatest incidence of cancer patients compared to that of any other European nation.
The coronavirus has grown to pose a significant threat to public health because it causes such severe respiratory symptoms and is ever-evolving. Adult hospitalized patients with COVID-19 are the focus of ongoing research on the efficacy and safety of novel lyophilized treatment medicines. Within this context, Cipla, a worldwide pharmaceutical business, is getting attention for releasing CIPREMI, a remdesivir lyophilized powder for injection (100 mg). Manufacturers in the lyophilized injectable market are adopting cues from these developments to enhance access to the Emergency Use Authorization (EUA) medication approved by the USA Food and Drug Administration for people experiencing severe COVID-19 symptoms.
With the third wave of the pandemic hitting India, manufacturers in the lyophilized injections industry there are stepping up their efforts to secure regulatory permission from the Drug Controller General of India (DCGI) for limited emergency use in the country.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Major players catering to the global demand for lyophilized injectables are showing a rising interest in the creation of drug delivery systems that are universal, upgradeable, and configurable. To do this, they are putting a significant amount of money into research and development-related operations.
A trend toward the incorporation of electronic components into injectors and other types of devices is likely to emerge among industry participants in the years to come. It is anticipated that these capabilities are expected to permit modification as per the user type that is proposed. Soon, it's anticipated that these devices' networking capabilities will allow for remote upgrades. As of this element, the process of managing the lifecycle of these devices is anticipated to become less difficult.
Key players in this industry rely on a strategy of continuous product development and improvement to meet the needs of their clients throughout the world and maintain their reputation in the cutthroat global lyophilized injectable market. In April of 2022, for instance, Recipharm purchased both the advanced therapy CDMO (Contract Development and Manufacturing Organization) Arranta Bio and the virotherapy CDMO Vibalogics. As a result of the purchase, Recipharm now has a sturdy foundation in the USA owing to its new Boxborough, Massachusetts facilities, and a solid foundation upon which to expand its capabilities into other biologics modalities.
The growth outlook for the Lyophilized Injectable market is predicted to advance at a CAGR of 5.8% from 2022 to 2032.
Europe region is anticipated to lead the Lyophilized Injectable market over the forecast period.
The valuation of the Lyophilized Injectable market stands at US$ 3043.55 Million in 2023.
The Lyophilized Injectable market is likely to hold a valuation of US$ 5348.56 Million by 2033.
1. Executive Summary | Lyophilized Injectable Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type of Packaging
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type of Packaging, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Packaging, 2022 to 2032
5.3.1. Single-use Vials
5.3.2. Point-of-care Reconstitution
5.3.3. Specialty Packaging
5.4. Y-o-Y Growth Trend Analysis By Type of Packaging, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Type of Packaging, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type of Delivery
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type of Delivery, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Delivery, 2022 to 2032
6.3.1. Prefilled Diluent Syringes
6.3.2. Proprietary Reconstitution Devices
6.3.3. Single-step Devices
6.3.4. Multi-step Devices
6.4. Y-o-Y Growth Trend Analysis By Type of Delivery, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Type of Delivery, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2022 to 2032
7.3.1. Autoimmune Diseases
7.3.2. Infectious Diseases
7.3.3. Metabolic Conditions
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Specialty Clinics
8.3.4. Others
8.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
8.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East and Africa(MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Type of Packaging
10.2.3. By Type of Delivery
10.2.4. By Indication
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type of Packaging
10.3.3. By Type of Delivery
10.3.4. By Indication
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Type of Packaging
11.2.3. By Type of Delivery
11.2.4. By Indication
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type of Packaging
11.3.3. By Type of Delivery
11.3.4. By Indication
11.3.5. By End User
11.4. Key Takeaways
12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Type of Packaging
12.2.3. By Type of Delivery
12.2.4. By Indication
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type of Packaging
12.3.3. By Type of Delivery
12.3.4. By Indication
12.3.5. By End User
12.4. Key Takeaways
13. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.1.4. India
13.2.1.5. Malaysia
13.2.1.6. Singapore
13.2.1.7. Australia
13.2.1.8. New Zealand
13.2.1.9. Rest of Asia Pacific
13.2.2. By Type of Packaging
13.2.3. By Type of Delivery
13.2.4. By Indication
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type of Packaging
13.3.3. By Type of Delivery
13.3.4. By Indication
13.3.5. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of Middle East and Africa(MEA)
14.2.2. By Type of Packaging
14.2.3. By Type of Delivery
14.2.4. By Indication
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type of Packaging
14.3.3. By Type of Delivery
14.3.4. By Indication
14.3.5. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Type of Packaging
15.1.2.2. By Type of Delivery
15.1.2.3. By Indication
15.1.2.4. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Type of Packaging
15.2.2.2. By Type of Delivery
15.2.2.3. By Indication
15.2.2.4. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Type of Packaging
15.3.2.2. By Type of Delivery
15.3.2.3. By Indication
15.3.2.4. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Type of Packaging
15.4.2.2. By Type of Delivery
15.4.2.3. By Indication
15.4.2.4. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Type of Packaging
15.5.2.2. By Type of Delivery
15.5.2.3. By Indication
15.5.2.4. By End User
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Type of Packaging
15.6.2.2. By Type of Delivery
15.6.2.3. By Indication
15.6.2.4. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Type of Packaging
15.7.2.2. By Type of Delivery
15.7.2.3. By Indication
15.7.2.4. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Type of Packaging
15.8.2.2. By Type of Delivery
15.8.2.3. By Indication
15.8.2.4. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Type of Packaging
15.9.2.2. By Type of Delivery
15.9.2.3. By Indication
15.9.2.4. By End User
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Type of Packaging
15.10.2.2. By Type of Delivery
15.10.2.3. By Indication
15.10.2.4. By End User
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Type of Packaging
15.11.2.2. By Type of Delivery
15.11.2.3. By Indication
15.11.2.4. By End User
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Type of Packaging
15.12.2.2. By Type of Delivery
15.12.2.3. By Indication
15.12.2.4. By End User
15.13. Malaysia
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Type of Packaging
15.13.2.2. By Type of Delivery
15.13.2.3. By Indication
15.13.2.4. By End User
15.14. Singapore
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Type of Packaging
15.14.2.2. By Type of Delivery
15.14.2.3. By Indication
15.14.2.4. By End User
15.15. Australia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Type of Packaging
15.15.2.2. By Type of Delivery
15.15.2.3. By Indication
15.15.2.4. By End User
15.16. New Zealand
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Type of Packaging
15.16.2.2. By Type of Delivery
15.16.2.3. By Indication
15.16.2.4. By End User
15.17. GCC Countries
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Type of Packaging
15.17.2.2. By Type of Delivery
15.17.2.3. By Indication
15.17.2.4. By End User
15.18. South Africa
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Type of Packaging
15.18.2.2. By Type of Delivery
15.18.2.3. By Indication
15.18.2.4. By End User
15.19. Israel
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Type of Packaging
15.19.2.2. By Type of Delivery
15.19.2.3. By Indication
15.19.2.4. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type of Packaging
16.3.3. By Type of Delivery
16.3.4. By Indication
16.3.5. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. B. Braun Melsungen AG
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Baxter International, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. BD
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Schott AG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Aristopharma Ltd.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Vetter Pharma
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Jubilant HollisterStier LLC
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. among others
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Lyophilized Injectable Market
